Brief, High-dose rTMS for Depression

Eligibility Criteria

• * A negative urine pregnancy test, if female subject of childbearing potential.
• * Able to speak English and complete study forms, adhere to treatment regimens, and be willing to return for regular visits.
• * After full explanation of the study, willingness of participant is demonstrated by signing the informed consent form.
• * Clinically unstable medical disease:
• * cardiovascular
• * renal
• * gastrointestinal
• * pulmonary
• * metabolic
• * endocrine
• * other
• * CNS disease deemed progressive
• * Moderate or severe traumatic brain injury (TBI)
• * Pregnant females or those currently breast-feeding.
• * Current or history of schizophrenia or other psychotic disorder, except psychosis not otherwise specified (NOS) when the presence of sensory hallucinations is clearly related to the subject's trauma, Bipolar Type I disorder, or dementia:
• * vascular
• * Alzheimer's disease
• * other types
• * Repeated abuse or dependence upon drugs (excluding nicotine and caffeine) within 6 days of study entry, with the exception of alcohol use disorder, which, at the discretion of the study team, may be permitted.
• * Active participation or plan for enrollment in another evidence-based psychotherapeutic clinical trial
• * Participation in other psychotherapeutic modalities must have been stable for 3 months prior to enrollment and must remain stable throughout participation.
• * Currently taking medications that have short half-lives, lower the seizure threshold, and do not have evidence of antidepressant efficacy. These include:
• * high dose theophylline or stimulants such as methylphenidate patients taking bupropion must be on a stable dose and take less than or equal to 300 mg/day. Stable means the same dose for 5 half-lives.
• * An implanted device in subject's head (shunt, cochlear implant) and/or metal in subject's head (other than dental implant).
• * History of seizures or a seizure disorder.